drugset
drugset / Trial / NCT00002921

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

NCT00002921 ↗

Phase 2 Terminated 13 enrolled SWOG Cancer Research Network National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.

Timeline

Start
1997-03
Primary completion
2004-01
Completion
2004-01

Publications

  • Results Shroder LE, Glass T, Eisenberger M, et al.: Phase II evaluation of suramin in advanced adrenal carcinoma: Southwest Oncology Group (SWOG) trial 9427. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-2361, 153b, 2001.

Drugs

EvaluationDrugModalityDoseRoute
Subject suramin Small molecule — Intravenous
Background Hydrocortisone Other / unclassified — Oral

Indications

adrenal cortex carcinoma